期刊文献+

Stathmin特异性siRNA表达质粒抑制stathmin的表达

Stathmin-specific siRNA expression plasmid inhibits the expression of stathmin
下载PDF
导出
摘要 目的:构建微管解聚蛋白stathmin基因的特异性siRNA质粒表达载体,以便研究stathmin在鼻咽癌中的生物学作用。方法:合成stathmin特异性DNA片段,退火形成的双链DNA片段克隆于质粒表达载体pGenesil-1.3;载体经扩增后,进行酶切和测序鉴定;采用QIAGEN公司脂质体(effectenetransfectionreagent)将鉴定后的重组质粒转入鼻咽癌CNE2细胞;RT-PCR与Westernblot检测stathmin基因表达。结果:酶切和测序分析表明,插入siRNA质粒表达载体中的DNA片段,其碱基序列和插入方向正确。表达分析证实特异性siRNA质粒表达载体能有效抑制鼻咽癌CNE2细胞中stathmin的表达。结论:构建的siRNA质粒表达载体对stathmin的表达有很好的抑制作用。 Objective Construct microtubule depolymerizing protein stathmin specific siRNA expression plasmid vector and study the biological function of stathmin in nasopharyngeal carcinoma.Methods Synthesize stathmin specific DNA fragments and anneal them to form double-strand DNA fragment.Subclone the DNA fragment into plasmid expression vector pGenesil-1.3.After the vector was amplified,it was identified by enzyme digestion and sequencing.Then,the identified recombinant plasmid vector was transferred into nasopharyngeal carcinoma CNE2 cell line by effectene transfection reagent of QIAGEN Company.Expression of stathmin was analyzed by RT-PCR and western blot.Results Enzyme digestion and sequencing data showed that siRNA expression plasmid vectors had been inserted stathmin-specific DNA fragment with right direction.Expression analysis confirmed that stathmin specific siRNA expression plasmid vector could effectively inhibit stathmin expression in nasopharyngeal CNE2 cells.Conclusion Recombinant stathmin specific siRNA expression plasmid vector can silence stathmin.
出处 《实用医学杂志》 CAS 北大核心 2012年第4期534-537,共4页 The Journal of Practical Medicine
基金 广西科学研究与技术开发课题(编号:桂科攻0816004-20) 国家自然科学基金(编号:81060178)
关键词 STATHMIN RNA干扰 质粒 基因治疗 Stathmin RNAi Plasmid Gene therapy
  • 相关文献

参考文献9

  • 1Houghtaling B R,Yang G,Matov A,et al.Op18 reveals the contribution of nonkinetochore microtubules to the dynamic organization of the vertebrate meiotic spindle[J].Proc Natl Acad Sci USA,2009,106(36):15338-15343.
  • 2Rana S,Maples P B,Senzer N,et al.Stathmin 1:a novel therapeutic target for anticancer activity[J].Expert Rev Anticancer Ther,2008,8(9):1461-1470.
  • 3Fire A,Xu S,Montgomery M K,et al.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J].Nature,1998,391(6669):806-811.
  • 4Yang J,Yuan Y A.A structural perspective of the protein-RNA interactions involved in virus-induced RNA silencing and its suppression[J].Bioehim Biophys Acta,2009,1789(9-10):642-652.
  • 5Pratt A J,MacRae I J.The RNA-induced silencing complex:a versatile gene-silencing machine[J].J Biol Chem,2009,284(27):17897-17901.
  • 6胡海燕,郭洪波,孟伟,董瑞红,陆琳,潘石蕾.MRP-siRNA逆转子宫内膜癌细胞多药耐药的研究[J].实用医学杂志,2010,26(16):2892-2894. 被引量:2
  • 7Holmfeldt P,Stenmark S,Gullberg M.Interphase specific phosphorylation-mediated regulation of tubulin dimer partitioning in human cells[J].Mol Biol Cell,2007,18(5):1909-1917.
  • 8Jeon T Y,Han M E,Lee Y W,et al.Overexpression of stathminl in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells[J].Br J Cancer,2010,102(4):710-718.
  • 9Singer S, Malz M, Herpel E, et al. Coordinated expression of stathmin family members by far upstream sequence elementbinding protein-1 increases motility in non-small cell lung cancer[J]. Cancer Res, 2009, 69(6):2234-2243.

二级参考文献9

  • 1Esteller M, Xercavins J, Reventos J. Advances in the molecular genetics of endometrial cancer (Review) [ J ]. Oncol Rep, 1999, 6(6) : 1377-1382.
  • 2Koshiyama M, Fujii H, Kinezaki M, et al. Immunohistochemical expression of topoisomerase Ⅱalpha (Topo Ⅱalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas [ J ]. Anticancer Res, 2001,21 (4B) : 2925-2932.
  • 3Brummelkamp T R, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells [J]. Science, 2002,296(5567) :550-553.
  • 4Takai N, Narahara H. Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer [J]. Obstet Gynecol Int, 2010,2010 : 923824.
  • 5De Marzi P, Frigerio L, Cipriani S, et al. Adjuvant treatment with concomitant radiotherapy and chemotherapy in high-risk endometrial cancer: a clinical experience [J]. Gynecol Oncol, 2010, 116(3) :408-412.
  • 6Mao Y, Wan X, Chen Y, et al. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma [J]. Fertil Steril, 2010,93 ( 1 ) : 283-285.
  • 7Nemati F, Daniel C, Arvelo F, et al. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts [J]. Anticancer Drugs, 2010,21 ( 1 ) : 25-32.
  • 8Shi D, Shi G, Huang G, et al. Chemosensitivity of radioresistant ceils in the multicellular spheroids of A549 lung adenocarcinoma [J]. J Exp Clin Cancer Res, 2009,28:72.
  • 9Gaikwad A, Wolf J K, Brown J, et al. In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines [J]. J Oncol Pharm Pract, 2009,15 (1) :35-44.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部